Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas - PubMed (original) (raw)
Review
Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas
Robert T Jensen. Basic Clin Pharmacol Toxicol. 2006 Jan.
Free article
Abstract
Proton pump inhibitors are being increasingly used and for longer periods of time, especially in patients with gastroesophageal reflux disease. Each of these trends has led to numerous studies and reviews of the potential risk-benefit ratio of the long-term use of proton pump inhibitors. Both long-term effects of hypergastrinaemia due to the profound acid suppression caused by proton pump inhibitors as well as the effects of hypo-/achlorhydria per se have been raised and studied. Potential areas of concern that have been raised in the long-term use of proton pump inhibitors, which could alter this risk-benefit ratio include: gastric carcinoid formation; the development of rebound acid hypersecretion when proton pump inhibitor treatment is stopped; the development of tolerance; increased oxyntic gastritis in H. pylori patients and the possibility of increasing the risk of gastric cancer; the possible stimulation of growth of non-gastric tumours due to hypergastrinaemia; and the possible effect of the hypo/achlorhydria on nutrient absorption, particularly iron and vitamin B12. Because few patients with idiopathic gastro-oesophageal reflux disease/peptic ulcer disease have been treated long-term (i.e., >10 years), there is little known to address the above areas of potential concern. Most patients with gastrinomas with Zollinger-Ellison syndrome have life-long hypergastrinaemia, require continuous proton pump inhibitors treatment and a number of studies report results of >5-10 years of tratment and follow-up. Therefore, an analysis of Zollinger-Ellison syndrome patients can provide important insights into some of the safety concerns raised above. In this paper, results from studies of Zollinger-Ellison syndrome patients and other recent studies dealing with the safety concerns above, are briefly reviewed.
Comment in
- Assessment of the risk of iatrogenic hypergastrinaemia from patients with gastrinoma.
Waldum H. Waldum H. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):3. doi: 10.1111/j.1742-7843.2006.pto_378b.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16433885 No abstract available.
Similar articles
- Assessment of the risk of iatrogenic hypergastrinaemia from patients with gastrinoma.
Waldum H. Waldum H. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):3. doi: 10.1111/j.1742-7843.2006.pto_378b.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16433885 No abstract available. - Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. Miyamoto M, et al. J Gastroenterol Hepatol. 2007 May;22(5):639-44. doi: 10.1111/j.1440-1746.2007.04871.x. J Gastroenterol Hepatol. 2007. PMID: 17444849 Clinical Trial. - Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
Delaney B, McColl K. Delaney B, et al. Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:32-40. doi: 10.1111/j.1365-2036.2005.02607.x. Aliment Pharmacol Ther. 2005. PMID: 16042657 Review. - Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Rauws EA. Rauws EA. Ital J Gastroenterol Hepatol. 1997 Dec;29(6):569-73. Ital J Gastroenterol Hepatol. 1997. PMID: 9513835 Review.
Cited by
- Effectiveness of Omeprazole in Acid Peptic Disease: A Real-World, Patient-Reported Outcome Measures Study.
Jain S, Shamrao Kulkarni S, Mahapatra JR, Todi D, Petare AU, Banerjee R, Rathod R, Naqvi S, Mane A, Dhanaki G, Kotak BP. Jain S, et al. Cureus. 2023 Jul 17;15(7):e41994. doi: 10.7759/cureus.41994. eCollection 2023 Jul. Cureus. 2023. PMID: 37593315 Free PMC article. - Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper.
Raoul JL, Edeline J, Simmet V, Moreau-Bachelard C, Gilabert M, Frénel JS. Raoul JL, et al. Cancers (Basel). 2022 Feb 24;14(5):1156. doi: 10.3390/cancers14051156. Cancers (Basel). 2022. PMID: 35267464 Free PMC article. Review. - Effects of Proton Pump Inhibitor Therapy, H. pylori Infection and Gastric Preneoplastic Pathology on Fasting Serum Gastrin Concentrations.
Veysey-Smith R, Moore AR, Murugesan SV, Tiszlavicz L, Dockray GJ, Varro A, Pritchard DM. Veysey-Smith R, et al. Front Endocrinol (Lausanne). 2021 Nov 18;12:741887. doi: 10.3389/fendo.2021.741887. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34867785 Free PMC article. - Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.
Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Singh SP, et al. Indian J Gastroenterol. 2021 Aug;40(4):420-444. doi: 10.1007/s12664-021-01186-4. Epub 2021 Jul 5. Indian J Gastroenterol. 2021. PMID: 34219211
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical